APS SENEGAL-PRESIDENTIELLE-REACTIONS / Washington et Ottawa félicitent Bassirou Diomaye Faye pour sa ‘’victoire électorale’’ AGP GUINÉE : L’APAC ÉCHANGE AVEC LA PRESSE SUR LA PRATIQUE DU JOURNALISME PAR LES FEMMES AGP GUINÉE : LE PM ÉCHANGE AVEC LE PRÉSIDENT DU CONSORTIUM WINNING SIMANDOU APS SENEGAL-INSTITUTIONS-PASSATION / Macky Sall invite le gouvernement à préparer les dossiers de passation de pouvoirs APS SENEGAL-GAMBIE-SOCIETE / Des patrouilles mixtes sénégalo-gambiennes pour prévenir les différends frontaliers APS SENEGAL-CULTURE-PERSPECTIVES / Habib Léon Ndiaye rassure sur la mise en œuvre du Plan stratégique de développement du théâtre APS AFRIQUE-BENIN-FOOTBALL / Gernot Rohr, sélectionneur du Bénin : “Je n’ai pas la même profondeur de banc que l’effectif du Sénégal” APS AFRIQUE-INFRASTRUCTURES / La BOAD approuve un prêt de 23 milliards pour la route Labé-Mali-Kédougou-Fongolembi APS SENEGAL-FOOTBALL-FORMATION / Matam : NSFCI veut rendre ses joueurs plus “compétitifs” en maximisant leur visibilité APS SENEGAL-PRESIDENTIELLE-RESULTATS / Bassirou Diomaye Diakhar Faye déclaré vainqueur avec 54, 28 % (résultats provisoires)

AstraZeneca says new data proves vaccine is highly effective


  25 Mars      38        Santé (15314),

 

London, March 25, (dpa/GNA) – The British-Swedish pharmaceuticals company AstraZeneca has provided new data which it says proves that its Covid-19 vaccine is highly effective.
The vaccine has a 76-per-cent efficacy rating against symptomatic Covid-19, AstraZeneca said in a statement on Thursday morning, citing further data from its phase III study with around 32,500 test subjects.
For people over 65, the efficacy rating is 85 per cent, the company added. This means that among the older subjects in a vaccinated group, 85 per cent fewer cases of illness occurred than among those in a control group.
AstraZeneca spoke of 100-per-cent efficacy against severe or critical illness and hospitalization.
One of the figures issued on Thursday is lower than the one issued on Monday, however: On Monday, the company had said that its vaccine was 79 per cent effective against Covid-19.
The drugmaker had promised to provide more data after questions were raised by a US health agency earlier in the week over possibly « outdated » vaccine trial results.
On Tuesday, the National Institute of Allergy and Infectious Diseases (NIAID) had said concerns were raised by the Data and Safety Monitoring Board (DSMB) over initial results published by AstraZeneca from its vaccine trials.
AstraZeneca said the new data confirmed vaccine efficacy consistent with the figures announced on Monday, March 22.
The drugmaker also noted that, according to the latest data, the vaccine was well-tolerated, and no safety concerns related to the vaccine were identified.
The British-Swedish company developed the vaccine called AZD1222 together with Oxford University. It has been used extensively in Britain since January.
Germany and several other countries had suspended vaccinations with the AstraZeneca substance for the time being because several cases of cerebral blood clots were reported in relation to vaccination with the substance. The vaccine is being used again.

Dans la même catégorie